Autonomix Medical, Inc. 10-K — AI Bull & Bear Analysis

The Autonomix 10-K reveals a classic high-risk, high-reward medtech profile where a potentially disruptive technology is colliding with a severe liquidity crunch. The company has successfully built a formidable IP moat with 75 issued patents, but it has yet to prove the efficacy of its proprietary devices in human trials, having relied on off-the-shelf equipment for early proof-of-concept work. The transition to US-based IDE trials in late 2026 represents the critical inflection point for the business. Investors are now weighing the possibility of a category-defining breakthrough in nerve-targeted therapy against the very real possibility of insolvency or delisting. The path to 2028, the targeted timeframe for De Novo FDA clearance, requires not only clinical success but a series of successful capital raises in a challenging market for pre-revenue biotech. The outcome will depend on whether the company can translate its technical sensing capabilities into consistent clinical outcomes that attract the necessary institutional backing to survive its current cash burn.